CCO Management Series
Diagnosis, Treatment, and Chronic Care Options for Hepatitis B
Chronic Hepatitis B: Epidemiology, Diagnosis, and Testing |
Module 1 of 4 |
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Topics covered include:
- Introduction
- Prevalence
- Definitions, Terminology, and Assays
- HBV Coinfections
- Serologic Diagnosis
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the diagnostic approaches to hepatitis B virus infection. Discuss the natural history of chronic hepatitis B, including the progression of liver disease to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Review the currently recommended approaches for the treatment of chronic hepatitis B, including special populations such as immunosuppressed patients and pregnant women.
|
Diagnosis and Treatment Options for Chronic Hepatitis B |
Module 2 of 4 |
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
- Emmet B. Keeffe, MD, MACP
|
|
|
Topics covered include:
- Overview
- Introduction
- Phases of Natural History in Chronic HBV Infection
- Cirrhosis and Hepatocellular Carcinoma
- Diagnosis
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the current and emerging treatment choices in chronic hepatitis B, including advantages and disadvantages of each treatment option. Discuss the different prophylactic and treatment approaches for various individual HBV- infected populations, including HBeAg(+) vs (-), coinfected patients, pregnant women, and immunocompromised individuals. Describe the natural history of chronic hepatitis B virus infection, and factors involved in proper diagnosis.
|
Long-Term Management of Patients with Chronic Hepatitis B Virus Infection |
Module 3 of 4 |
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Topics covered include:
- Introduction
- HBV Infection Is Life Long
- Clinical Course of Chronic HBV Infection is Highly Variable
- Immune Tolerant Phase (HBeAg-positive chronic hepatitis with normal ALT
- Immune Clearance Phase (HBeAg-positive chronic hepatitis
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the safety and efficacy of currently available treatments for chronic HBV infection. Review the elements of disease assessment, counseling, monitoring, and initial treatment decisions in chronic HBV infection. Discuss the natural history of chronic HBV infection, including the clinical phases, and factors impacting disease activity and progression.
|
Hepatitis B: Prevention of Cirrhosis and Hepatocellular Carcinoma |
Module 4 of 4 |
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
- Adrian M. Di Bisceglie, MD, FACP
|
|
|
Topics covered include:
- Introduction
- Natural History of Hepatitis B
- Assessment of HBV Disease
- Effect of Antiviral Therapy on Progression to Cirrhosis
- Effect of Antiviral Therapy on Patients Who Have Cirrhosis
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the diagnostic approaches to hepatitis B virus infection. Discuss the natural history of chronic hepatitis B, including the progression of liver disease to cirrhosis, end-stage disease, and hepatocellular carcinoma. Review the currently recommended approaches for the treatment of chronic hepatitis.
|
Interactive Case Challenges
Management of Severe HBV Infection in the Pre- and Post-Transplant Setting
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Test your ability to provide optimal clinical management for decompensated patient with chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the potential clinical benefits and risks associated with the use of nucleoside analogues in patients with decompensated HBV liver disease Outline the potential role of tenofovir in the treatment of chronic HBV infection Review data on the use of immunoprophylaxis to prevent HBV recurrences after liver transplantation
|
Management of Liver Disease in an HBV/HIV-Coinfected Patient
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Consider the treatment options for a coinfected patient whose treatment regimen did not necessarily take his HBV infection into account.
Learning Objectives
Upon completion of this activity, participants should be able to:
Outline the risks and monitoring guidelines for HBV infection in HIV-infected individuals Describe the potential advantages and disadvantages of various antiviral medications for the treatment of HBV in HIV-infected patients Review the risks for hepatocellular carcinoma development in HBV-monoinfected patients and HBV/HIV-coinfected patients
|
Management of HBeAg-negative Chronic Hepatitis B in a Patient with Advanced Liver Disease
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Explore options and receive feedback on your choices of therapy for a challenging patient with advanced liver disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe advantages and disadvantages of current treatment choices for HBeAg-negative chronic hepatitis B patients Outline management of HBeAg-negative chronic hepatitis B patients on antiviral treatment Review guidelines for initiating treatment in individuals with HBeAg-negative chronic hepatitis B
|
A 42-year-old White Man With Chronic Hepatitis B and a Worried Wife
|
CME Program Director: Patrick J. Lynch, MD
Program Director: Eugene R. Schiff, MD, MACP, FRCP, MACG
|
|
Consider appropriate clinical management choices for both an infected patient and his immediate family.
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the approach to a stable sexual partner and household contacts of a patient with chronic hepatitis B. Evaluate the various treatment options for a chronic hepatitis B patient with fibrosis or cirrhosis. Discuss the management considerations for a chronic hepatitis B patient with depression.
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Pharmacist and nursing credit provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|